Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PACERONE vs VISIONBLUE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Class III antiarrhythmic agent; prolongs action potential duration and refractory period by blocking potassium channels, and also exhibits class I, II, and IV effects.
Visionblue (trypan blue) is a dye that selectively stains the anterior lens capsule and vitreous, enhancing visualization during ophthalmic surgeries such as cataract extraction and vitrectomy. It does not exert pharmacological activity but acts as a vital stain.
Life-threatening recurrent ventricular arrhythmias (e.g., ventricular fibrillation, hemodynamically unstable ventricular tachycardia),Atrial fibrillation and atrial flutter (off-label may include maintenance of sinus rhythm)
Staining of the anterior lens capsule during cataract surgery or capsulorhexis,Staining of vitreous in vitrectomy procedures
Loading dose: 800-1600 mg/day PO in divided doses for 1-3 weeks, then 600-800 mg/day PO for 1 month; maintenance: 200-400 mg/day PO once daily. IV: 150 mg over 10 min, then 1 mg/min for 6 hours, then 0.5 mg/min.
0.5 m L of 0.025% solution intracameral injection (single use).
Biphasic: initial 3-10 days; terminal elimination half-life 40-58 days (mean ~53 days) due to extensive tissue distribution and slow release from fat. Clinical context: steady-state achieved in 2-4 months without loading dose.
Approximately 2.5 hours in patients with normal renal function; prolonged in renal impairment (up to 12 hours).
Primarily hepatic via CYP3A4 and CYP2C8; active metabolite desethylamiodarone; substrate of P-glycoprotein.
Visionblue is not metabolized; it is cleared from the eye via aqueous humor outflow and systemic absorption is negligible.
Primarily hepatic metabolism (CYP3A4, CYP2C8) to desethylamiodarone (active). Renal elimination of drug and metabolites: <1% of unchanged drug; ~40% of dose as metabolites. Fecal elimination: ~70% of dose as metabolites, with some parent drug.
Primarily eliminated unchanged via renal glomerular filtration; minimal biliary excretion (<5%).
96% bound, primarily to albumin and beta-lipoproteins.
Negligible (<5%), primarily to albumin.
66 L/kg (range 10-200 L/kg) indicating extensive tissue distribution, especially in adipose tissue, liver, and lungs.
0.2 L/kg, reflecting confinement to extracellular fluid and minimal tissue binding.
Oral: 30-80% (mean ~50%), increased by food; erratic absorption due to high lipophilicity. IV: 100%.
Not applicable for systemic routes; intraocular administration yields direct local effect.
No specific GFR-based dose adjustment required; caution in severe renal impairment due to possible accumulation of active metabolite desethylamiodarone. Monitor serum levels and QT interval.
No dosage adjustment required; VISIONBLUE is not systemically absorbed.
Contraindicated in severe hepatic disease (Child-Pugh class C). In moderate impairment (Child-Pugh class B), reduce maintenance dose by 50% and monitor liver function. Mild impairment (Child-Pugh A): no adjustment, but monitor.
No dosage adjustment required; VISIONBLUE is not systemically absorbed.
Loading: 10-20 mg/kg/day PO in divided doses for 7-10 days; maintenance: 5-10 mg/kg/day PO once daily. IV loading: 5 mg/kg over 30 min, then 5-15 mg/kg/day continuous infusion.
Safety and efficacy not established in pediatric patients; no standard dosing available.
Lower maintenance doses (100-200 mg/day PO) due to increased risk of bradycardia, QT prolongation, and thyroid dysfunction. Monitor renal function and electrolytes closely.
No specific adjustment; use adult dosing as indicated.
Only for patients with life-threatening arrhythmias due to risk of pulmonary toxicity, hepatotoxicity, and proarrhythmia; requires baseline and periodic monitoring of pulmonary function, liver enzymes, thyroid function, and ECG.
None
Pulmonary toxicity (interstitial pneumonitis, pulmonary fibrosis), hepatotoxicity (elevated liver enzymes, hepatic failure), proarrhythmia (worsening arrhythmias, torsades de pointes), thyroid dysfunction (hypo- or hyperthyroidism), optic neuropathy/neuritis, skin discoloration, photosensitivity, bradycardia, and drug interactions (CYP450 and P-gp mediated).
Intraocular use only; do not inject intravenously,Potential for corneal endothelial toxicity if excessive volume or prolonged contact,May cause transient increase in intraocular pressure,Hypersensitivity reactions have been reported,Use with caution in patients with compromised corneal endothelium
Cardiogenic shock, severe sinus node dysfunction (without pacemaker), second- or third-degree AV block (without pacemaker), marked bradycardia, and hypersensitivity to amiodarone or iodine.
Known hypersensitivity to trypan blue or any component of the formulation,Intraocular use in patients with significant corneal endothelial compromise
Avoid grapefruit juice as it inhibits CYP3A4 and can increase amiodarone levels. St. John's wort may decrease amiodarone efficacy by inducing metabolism. Take with food to reduce gastrointestinal irritation.
No known food interactions. This drug is administered intraocularly and is not ingested; systemic absorption is negligible.
Pacerone (amiodarone) is FDA Pregnancy Category D. First trimester: risk of congenital anomalies including hypothyroidism, goiter, and neurodevelopmental delays due to iodine content. Second and third trimesters: continued risk of fetal hypothyroidism and bradycardia; neonatal monitoring for thyroid function and ECG is recommended.
No teratogenic effects in animal studies; limited human data. Avoid use in pregnancy unless benefits outweigh risks.
Amiodarone is excreted into breast milk with an M/P ratio of approximately 0.1-1.0. Due to significant accumulation in infant tissues and long half-life, breastfeeding is contraindicated because of potential for neonatal hypothyroidism and bradycardia.
Minimal systemic absorption; M/P ratio not reported. Compatible with breastfeeding but avoid direct infant eye contact.
Pregnancy increases volume of distribution and clearance of amiodarone, potentially requiring dose adjustments to maintain therapeutic levels. However, due to risks, use is limited to severe arrhythmias and doses should be minimized. Monitoring of serum levels is recommended to guide dosing.
No dosage adjustment needed; pharmacokinetics unchanged in pregnancy.
Amiodarone has an extremely long half-life (up to 107 days) causing delayed onset and prolonged effects. Monitor for thyroid dysfunction, pulmonary fibrosis, liver toxicity, and corneal deposits. Avoid coadministration with drugs prolonging QT interval. Use lowest effective dose due to cumulative toxicity.
Vision Blue (trypan blue ophthalmic solution 0.06%) is a vital dye used as a surgical aid in cataract surgery for staining the anterior capsule during capsulorhexis. It selectively stains the anterior lens capsule due to its affinity for basement membranes, facilitating visualization in eyes with poor red reflex (e.g., white cataracts, dense brunescent cataracts). Avoid injecting into the vitreous; if encountered, perform anterior vitrectomy immediately. Use with caution in patients with pseudophakic or aphakic eyes due to risk of dye retention in the vitreous. Discard any unused solution after surgery; single-use vial only.
Take exactly as prescribed; do not skip doses or stop without consulting your doctor.,Report any new or worsening shortness of breath, cough, chest pain, or palpitations.,Inform your doctor if you experience vision changes, thyroid symptoms (weight change, heat/cold intolerance), or skin discoloration.,Avoid grapefruit juice and St. John's wort as they may affect drug levels.,Use sun protection; amiodarone increases sun sensitivity.,Do not breastfeed while taking this medication.,Keep all follow-up appointments for blood tests, eye exams, and lung function tests.,This medication can cause birth defects; use effective contraception.
This medication is used during eye surgery to help your surgeon see the lens capsule clearly.,It is not self-administered; it will be applied by your surgeon during the procedure.,Inform your surgeon about any allergies, especially to dyes or medications.,Report any eye pain, redness, or vision changes after surgery immediately.,You may experience temporary blue discoloration of the eye, which resolves within days.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PACERONE vs VISIONBLUE, answered by our medical review team.
PACERONE is a Antiarrhythmic Agent that works by Class III antiarrhythmic agent; prolongs action potential duration and refractory period by blocking potassium channels, and also exhibits class I, II, and IV effects.. VISIONBLUE is a Ophthalmic Dye/Stain that works by Visionblue (trypan blue) is a dye that selectively stains the anterior lens capsule and vitreous, enhancing visualization during ophthalmic surgeries such as cataract extraction and vitrectomy. It does not exert pharmacological activity but acts as a vital stain.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PACERONE and VISIONBLUE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PACERONE is: Loading dose: 800-1600 mg/day PO in divided doses for 1-3 weeks, then 600-800 mg/day PO for 1 month; maintenance: 200-400 mg/day PO once daily. IV: 150 mg over 10 min, then 1 mg/min for 6 hours, then 0.5 mg/min.. The standard adult dose of VISIONBLUE is: 0.5 m L of 0.025% solution intracameral injection (single use).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PACERONE and VISIONBLUE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PACERONE is classified as Category C. Pacerone (amiodarone) is FDA Pregnancy Category D. First trimester: risk of congenital anomalies including hypothyroidism, goiter, and neurodevelopmental delays due to iodine conte. VISIONBLUE is classified as Category C. No teratogenic effects in animal studies; limited human data. Avoid use in pregnancy unless benefits outweigh risks.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.